Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Frequency Therapeutics, Inc.

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Otolith Labs develops a noninvasive wearable solution for chronic vertigo through patented technology utilizing non-invasive Vestibular Resonance Therapy (nVRT).

Otolith Labs

Korro Bio focuses on editing a single letter on RNA to modulate biological pathways. The company aims to deliver genetic medicines to address complex prevalent diseases.

Metric
Company Name	Frequency Therapeutics, Inc.	Eterna Therapeutics Inc.	GC Therapeutics	Otolith Labs
Symbol	FREQ	ERNA
MSH ID	COM:FREQUENCYTX	COM:ETERNATX	COM:GC-TX	COM:OTOLITHLABS
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Medical Devices
Country	US	US	US	US
Stage			Series A
Employee Count	46	8
Website	frequencytx.com	brooklynitx.com	gc-tx.com	otolithlabs.com
LinkedIn
Founders

Metric
Market Cap	10.94M	9.90M
Enterprise Value
Monthly Web Traffic		270.57K	1.68K
Web Traffic Growth		0.55	-0.43
Valuation
Raised Capital			65M

Metric
Revenue		68K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-1.29M
EBITDA		-19.55M
Operating Income		-20.67M
Net Income		-21.67M
EPS		-4.08
Diluted EPS		-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-5.88
Operating Profit Margin		-135.73
EBITDA Margin		-287.51
Net Profit Margin		-147.65
Return on Equity		15.58
Return on Assets		-0.44
Return on Capital Employed		-0.50

COM:FREQUENCYTX

Korro Bio

Last Close

0.29

03/11 20:00

Market Cap

10.94M

Beta: -

Volume Today

309.16K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.42
P/B Ratio		2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		192.73
EV Multiple		2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding
Operating Cycle		2.28K
Cash Conversion Cycle		1.79K
Asset Turnover		0.00

Metric
Operating Cash Flow		-20.41M
Free Cash Flow		-20.43M
Cash Flow to Debt		-0.38
Operating Cash Flow/Sales		-101.81
Free Cash Flow Yield		-2.54

Metric
Cash & Equivalents		7.58M
Accounts Receivable		527K
Inventory
Goodwill		2.04M
Debt to Capitalization		2.84
Debt to Assets		0.79
Current Ratio		0.73
Quick Ratio		1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		28.90
R&D to Revenue		130.82
SG&A to Revenue		252.08